Investing in Engineering Biology to Transform Human and Planetary Health »

Arvind Gupta co-leads Mayfield’s Engineering Biology practice.  He was the first investor in breakout bio companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite and Memphis Meats.

As Founder of IndieBio, Arvind redefined the pace and possibilities of early stage biotech, investing in over 136 companies in five years, defining human and planetary health, and growing the IndieBio portfolio into billions of dollars in value. Under his leadership, IndieBio expanded to New York and grew to fifteen investment professionals with a world class adjunct partner board. He is now Venture Advisor at IndieBio.

Arvind is the author of Decoding the World: A Roadmap for the Questioner, published by Twelve Books, a division of the Hachette Publishing Group. He was honored with the F50 Global Award for Impact in HealthTech Innovation.  He is a frequent speaker at TechCrunch Disrupt, Slush, TedX and Future FoodTech.  His work has been profiled in global media outlets such as Bloomberg News, Forbes, The Guardian UK, Neo.life, Nikkei News, Rotman, The Times of India, and CGTN in China.  Arvind has been a guest lecturer at UCSF, MIT and Harvard and is a judge at the annual BIO conference startup stadium.

Prior to founding IndieBio, Arvind was Design Director at IDEO in Shanghai where he earned numerous international design awards and presented his work at the San Francisco Museum of Modern Art.

Arvind received his B.S. in Genetic Engineering from UCSB. He holds 8 patents.

Arvind is married to an Icelander and has two daughters.